NATCO Pharma Limited – FDA 483, Jun 19, 2025
An FDA inspection of NATCO Pharma Limited in Rangareddy, India, a sterile and non-sterile drug manufacturer, revealed significant deficiencies across its aseptic processing operations and quality control systems. Key issues included severe data integrity problems with environmental monitoring, inadequate aseptic process validation, poor facility maintenance, and a lack of thorough investigations into discrepancies and quality events. The findings indicate a systemic breakdown in quality oversight and adherence to cGMP requirements, particularly concerning sterile drug product manufacturing.
ID · f7f3273d-2be6-4f68-9f8f-a170de0e988e
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.